Table 2. Clinical characteristics of the 228 patients, compared according to whether there was recurrence during follow-up.
| Characteristic | Total (n=228) | Recurrence (n=85) | No recurrence (n=143) | P |
|---|---|---|---|---|
| Age (y) | 60.3±10.7 | 61.2±10.1 | 59.7±11.0 | 0.329 |
| Age ≥60 years | 123 (53.9) | 53 (62.4) | 70 (49.0) | 0.050 |
| Female | 157 (68.9) | 56 (65.9) | 101 (70.6) | 0.454 |
| BMI (kg/m2) | 20.6±2.6 | 20.7±2.3 | 20.6±2.8 | 0.784 |
| Current or past smoker | 43 (18.9) | 15 (17.6) | 28 (19.6) | 0.718 |
| Previous history of TB treatment | 75 (32.9) | 33 (38.8) | 42 (29.4) | 0.142 |
| Previous history of NTM treatment | 14 (6.1) | 9 (10.6) | 5 (3.5) | 0.031 |
| Comorbidity | ||||
| COPD | 26 (11.4) | 10 (11.8) | 16 (11.2) | 0.895 |
| Diabetes mellitus | 17 (7.5) | 10 (11.8) | 7 (4.9) | 0.056 |
| Chronic liver disease | 17 (7.5) | 6 (7.1) | 11 (7.7) | 0.860 |
| Malignancy | 43 (18.9) | 18 (21.2) | 25 (17.5) | 0.491 |
| Etiology | 0.705 | |||
| Mycobacterium avium | 111 (48.7) | 40 (47.1) | 71 (49.7) | |
| Mycobacterium intracellulare | 117 (51.3) | 45 (52.9) | 72 (50.3) | |
| Positive AFB smear at treatment initiation | 77 (33.8) | 30 (35.3) | 47 (32.9) | 0.708 |
| Number of involved lobes | 3.5±1.3 | 3.7±1.3 | 3.4±1.3 | 0.079 |
| Use of injectable aminoglycosides | 87 (38.2) | 28 (32.9) | 59 (41.3) | 0.211 |
| Daily therapy | 222 (97.4) | 85 (100.0) | 137 (95.8) | 0.087 |
| Surgical resection | 5 (2.2) | 3 (3.5) | 2 (1.4) | 0.364 |
| Shorter treatment duration (9–11 months) | 59 (25.9) | 23 (27.1) | 36 (25.2) | 0.753 |
| Time to initiate treatment after diagnosis (months) | 5.2 (1.7–12.0) | 4.4 (1.1–11.9) | 5.3 (1.9–13.3) | 0.414 |
| Follow-up duration after treatment completion (months) | 56.1 (31.3–78.1) | 68.5 (46.5–91.1) | 45.0 (23.7–70.8) | <0.001 |
BMI, body mass index; TB, tuberculosis; NTM, nontuberculous mycobacteria; COPD, chronic obstructive lung disease; AFB, acid-fast bacilli. Data are presented as mean (± standard deviation), median (interquartile range), or number (%).